| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028201157 |
| P356 | DOI | 10.2165/00003495-200969110-00008 |
| P698 | PubMed publication ID | 19634927 |
| P2093 | author name string | M Asif A Siddiqui | |
| Katherine F Croom | |||
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| New horizons and perspectives in the treatment of osteoarthritis | Q24657795 | ||
| EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) | Q24675150 | ||
| A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. | Q24794291 | ||
| Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. | Q25257426 | ||
| Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease | Q28200044 | ||
| Inhibitors of cyclooxygenases: mechanisms, selectivity and uses | Q28217593 | ||
| Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
| Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk | Q28219220 | ||
| Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | Q31842803 | ||
| EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q33260652 | ||
| OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines | Q33320085 | ||
| Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice | Q33566361 | ||
| A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo | Q33633625 | ||
| Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis | Q33875514 | ||
| A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin | Q33952053 | ||
| Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. | Q34183755 | ||
| Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor | Q34515171 | ||
| Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers | Q34530443 | ||
| Pharmacokinetics of etoricoxib in patients with renal impairment | Q34544012 | ||
| The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis | Q34558759 | ||
| Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies | Q34570399 | ||
| Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. | Q34575707 | ||
| Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 | ||
| Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. | Q34653947 | ||
| Celecoxib inhibits 5-lipoxygenase | Q34656902 | ||
| Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib | Q34847583 | ||
| Etoricoxib | Q35016968 | ||
| Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. | Q35555160 | ||
| ASAS/EULAR recommendations for the management of ankylosing spondylitis | Q35637012 | ||
| EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q35638360 | ||
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials | Q35680546 | ||
| ??? | Q28199855 | ||
| Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis | Q35954438 | ||
| Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy | Q36285978 | ||
| The burden of musculoskeletal disease--a global perspective | Q36446201 | ||
| The burden of ankylosing spondylitis. | Q36623885 | ||
| Coxibs and heart disease: what we have learned and what else we need to know | Q36701215 | ||
| Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists | Q37085249 | ||
| Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). | Q41998132 | ||
| In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). | Q43591309 | ||
| Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers | Q43754371 | ||
| Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial | Q43997545 | ||
| A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. | Q44103550 | ||
| Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. | Q44123837 | ||
| Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo | Q44162505 | ||
| Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib | Q44282395 | ||
| Characterization of etoricoxib, a novel, selective COX-2 inhibitor | Q44484802 | ||
| The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events | Q44542155 | ||
| Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment | Q44601145 | ||
| A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis | Q44700625 | ||
| Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial | Q44762080 | ||
| Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. | Q44971339 | ||
| The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. | Q45040968 | ||
| Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs | Q45257806 | ||
| Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. | Q45940021 | ||
| Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. | Q45974086 | ||
| The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. | Q46011350 | ||
| Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program | Q46043878 | ||
| Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib | Q46382423 | ||
| Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study | Q46428507 | ||
| Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial | Q46428706 | ||
| Effects of etoricoxib on the pharmacokinetics of phenytoin. | Q46621565 | ||
| Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects | Q46628463 | ||
| Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans | Q46905036 | ||
| Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. | Q46923214 | ||
| Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). | Q46927526 | ||
| British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). | Q51853711 | ||
| A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. | Q51910355 | ||
| British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). | Q51937590 | ||
| Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib | Q57221140 | ||
| Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib | Q79695252 | ||
| The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin | Q80177912 | ||
| Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial | Q80793608 | ||
| Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib | Q83107186 | ||
| Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout | Q94534823 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| rheumatoid arthritis | Q187255 | ||
| ankylosing spondylitis | Q52849 | ||
| P304 | page(s) | 1513-1532 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis | |
| P478 | volume | 69 |
| Q53508065 | A distonic radical-ion for detection of traces of adventitious molecular oxygen (O2) in collision gases used in tandem mass spectrometers. |
| Q36163165 | A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis |
| Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
| Q47756560 | Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly |
| Q33880198 | Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis |
| Q34556831 | Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice |
| Q60678518 | Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects |
| Q53602109 | Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. |
Search more.